Boston Scientific Corporation
0HOY.L
London Stock Exchange45.05
USD
+0.15
- -
Boston Scientific Corporation
0HOY.L
(London Stock Exchange)
Recent
price
45.05
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Boston Scientific Corporation is a global medical technology company that develops, manufactures, and markets a broad range of medical devices and therapies primarily for cardiovascular, rhythm management, endoscopy, urology, pelvic health, and neuromodulation applications. Its core product portfolio includes drug-eluting stents, angioplasty balloons, embolization products, guidewires, electrophysiology catheters, implantable cardioverter defibrillators (ICDs), pacemakers, neurostimulation devices, structural heart products, and advanced endoscopy and urology devices. The company operates worldwide and targets healthcare providers specializing in interventional cardiology, electrophysiology, peripheral interventions, neuromodulation, and surgical specialties. Founded in 1979 and headquartered in Marlborough, Massachusetts, Boston Scientific serves a global market with extensive offerings across multiple medical specialties. Recent strategic developments include the acquisition agreements for Nalu Medical, Inc., which expands its neuromodulation offerings for chronic pain management, expected to complete in the first half of 2026; and the asset acquisition of Elutia, Inc., adding the EluPro BioEnvelope and CanGaroo Envelope designed to prevent complications related to cardiac devices. In 2024 and 2025, Boston Scientific finalized several significant acquisitions including the $3.7 billion purchase of Axonics and the $1.26 billion acquisition of Silk Road Medical, reinforcing its growth in urology and peripheral vascular markets. The company also advanced its portfolio through the acquisition of SoniVie Ltd. to include ultrasound-based renal denervation therapy and continues expanding innovative technologies such as the five-year clinical outcomes for deep brain stimulation in Parkinson's disease published in JAMA Neurology. Additionally, Boston Scientific reports strong financial performance with net sales growth exceeding 20 percent in third quarter 2025 and expects full-year organic sales growth around 15.5 percent, driven by its category leadership and innovation strategy. Boston Scientific’s product offerings are extensive and detailed, including drug-coated balloons, defibrillators (S-ICD, ICD), catheter systems, diagnostic imaging and physiology systems, endoscopic sleeve gastroplasty devices, embolic protection, guidewires, intragastric balloons, lasers, lithotripsy devices, and rhythm management solutions such as LATITUDE remote patient management. The company leverages innovations in interventional cardiology, oncology, radiology, and urology to support minimally invasive and advanced treatments globally. Its strategic alliances, acquisitions, and continuous product development underscore its commitment to expanding its therapeutic solutions and geographic footprint in key medical device markets worldwide. Boston Scientific remains a leader in the medical technology sector with a focus on improving patient outcomes and reducing healthcare costs through advanced, high-performance medical devices.